Who Qualifies for Weight Loss Injections on the NHS

Which BMI and conditions currently open the door to NHS tirzepatide?

Tirzepatide (branded as Mounjaro) was recommended by NICE in December 2024, and NHS England began phasing in access from June 2025. The first cohort to open required a BMI of 40 or above, plus four or more of a defined list of five weight-related conditions: high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, and type 2 diabetes. That is a narrow group deliberately, the NHS is managing both demand and clinical risk.

The second cohort activated in June 2026. It covers adults with a BMI of 35 to 39.9 who still have four or more of those five conditions. A third cohort is expected around March 2027, opening to BMI 40 or above with three conditions rather than four. Each step widens eligibility slightly, but the process is slow by design. You can read the full phased detail on what NHS tirzepatide access currently looks like and on the NICE TA1026 recommendations page.

Throughout all cohorts, BMI thresholds are reduced by 2.5 kg/m² for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds, reflecting the different cardiovascular risk profile at lower BMIs in those groups. If you want a detailed breakdown of who is eligible for weight loss injections on the NHS, including how these background-specific adjustments apply in practice, that page walks through the criteria cohort by cohort. And a BMI that clears the threshold is the starting point, not the finish line, the prescriber still reviews your full medical history before treatment begins.

Semaglutide (Wegovy) on the NHS: a different set of rules

Wegovy was approved by NICE under TA875 back in March 2023, and its NHS route looks quite different from tirzepatide's. Under TA875, semaglutide is recommended only within a specialist weight management service, a multidisciplinary setting that includes dietetic and psychological support, not just a prescription. The BMI bar is 35 or above with at least one weight-related comorbidity, or 30 to 34.9 if you meet specialist-referral criteria.

There are two further conditions that make this route harder to access in practice. First, treatment is recommended for a maximum of two years only. Second, the waiting lists for NHS specialist weight management services in many areas of England are long, sometimes over a year. If you live in Scotland, Wales or Northern Ireland, the criteria differ again; keep that framing in mind and check locally. The NHS England guidance on weight management injections gives the most up-to-date position for England.

From April 2026 some GP practices in England can prescribe tirzepatide directly under the new GP contract; participation is optional, so whether your practice offers this varies. Wegovy is not part of that GP-prescribing scheme, it remains in the specialist-service lane.

What happens if you meet the licensed criteria but not the NHS ones?

The licensed eligibility for both medicines is considerably broader than the NHS thresholds. The medicines regulators (the MHRA) license tirzepatide and semaglutide for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition. That covers far more people than the NHS currently funds. So if your BMI is 32 with hypertension, you are within the licensed population but outside the current NHS cohort.

Private treatment is the alternative for that group. A registered online pharmacy can prescribe these medicines for anyone who is clinically suitable under the licensed criteria, following a proper consultation with a GPhC-registered prescriber, no GP referral, no waiting list. The qualification process for NHS versus private routes is worth understanding side by side if you are weighing your options. One honest note: private treatment has a cost, and our guide to weight loss injections covers how these medicines work, what the treatment journey looks like, and what to expect from a private provider. The question of what that includes varies considerably between providers.

The practical gaps between qualifying on paper and getting treated

Even if your BMI and conditions place you inside a current NHS cohort, several real-world factors can delay or prevent access. GP practices opted into the new prescribing scheme are not uniformly distributed across England, rural areas and some urban practices have not signed up. If your practice has not, you would need a referral to a specialist service, which loops you back to the waiting-list problem.

NHS treatment also requires active participation in wrap-around lifestyle support, dietary guidance, activity coaching and follow-up. This is good medicine, but it means the prescription alone is not enough; you need to engage with the full programme. If you stop losing weight after six months on the maintenance dose (less than 5% body weight), NICE guidance recommends reviewing whether to continue.

Understanding who actually writes these prescriptions (and under what conditions) can help you decide which route is realistic for you right now, and it is also worth reading about who can get weight loss injections on the NHS to see whether the current cohort criteria match your situation before you decide between NHS and private options. If private treatment is on your radar, our clinical team at nume reviews every consultation personally, the same day it is submitted. Speak to our prescribers to find out whether you meet the criteria for private treatment.